BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 31218907)

  • 1. Beta-2 microglobulin knockout K562 cell-based artificial antigen presenting cells for
    Zha S; Li Z; Chen C; Du Z; Tay JC; Wang S
    Immunotherapy; 2019 Aug; 11(11):967-982. PubMed ID: 31218907
    [No Abstract]   [Full Text] [Related]  

  • 2. Peptide-beta2-microglobulin-major histocompatibility complex expressing cells are potent antigen-presenting cells that can generate specific T cells.
    Obermann S; Petrykowska S; Manns MP; Korangy F; Greten TF
    Immunology; 2007 Sep; 122(1):90-7. PubMed ID: 17472719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetically engineered fixed K562 cells: potent "off-the-shelf" antigen-presenting cells for generating virus-specific T cells.
    Tanimoto K; Muranski P; Miner S; Fujiwara H; Kajigaya S; Keyvanfar K; Hensel N; Barrett AJ; Melenhorst JJ
    Cytotherapy; 2014 Jan; 16(1):135-46. PubMed ID: 24176543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutant B2M-HLA-E and B2M-HLA-G fusion proteins protects universal chimeric antigen receptor-modified T cells from allogeneic NK cell-mediated lysis.
    Guo Y; Xu B; Wu Z; Bo J; Tong C; Chen D; Wang J; Wang H; Wang Y; Han W
    Eur J Immunol; 2021 Oct; 51(10):2513-2521. PubMed ID: 34323289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells.
    Dupont J; Latouche JB; Ma C; Sadelain M
    Cancer Res; 2005 Jun; 65(12):5417-27. PubMed ID: 15958591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificity.
    Rushworth D; Jena B; Olivares S; Maiti S; Briggs N; Somanchi S; Dai J; Lee D; Cooper LJ
    J Immunother; 2014 May; 37(4):204-13. PubMed ID: 24714354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules.
    Suhoski MM; Golovina TN; Aqui NA; Tai VC; Varela-Rohena A; Milone MC; Carroll RG; Riley JL; June CH
    Mol Ther; 2007 May; 15(5):981-8. PubMed ID: 17375070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors.
    Rossig C; Bär A; Pscherer S; Altvater B; Pule M; Rooney CM; Brenner MK; Jürgens H; Vormoor J
    J Immunother; 2006; 29(1):21-31. PubMed ID: 16365597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
    Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
    J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigen Presentation by Individually Transferred HLA Class I Genes in HLA-A, HLA-B, HLA-C Null Human Cell Line Generated Using the Multiplex CRISPR-Cas9 System.
    Hong CH; Sohn HJ; Lee HJ; Cho HI; Kim TG
    J Immunother; 2017; 40(6):201-210. PubMed ID: 28604557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes.
    Ye Q; Loisiou M; Levine BL; Suhoski MM; Riley JL; June CH; Coukos G; Powell DJ
    J Transl Med; 2011 Aug; 9():131. PubMed ID: 21827675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Artificial antigen-presenting cells are superior to dendritic cells at inducing antigen-specific cytotoxic T lymphocytes.
    Shao J; Xu Q; Su S; Wei J; Meng F; Chen F; Zhao Y; Du J; Zou Z; Qian X; Liu B
    Cell Immunol; 2018 Dec; 334():78-86. PubMed ID: 30392890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Possible detrimental effects of beta-2-microglobulin knockout in pigs.
    Sake HJ; Frenzel A; Lucas-Hahn A; Nowak-Imialek M; Hassel P; Hadeler KG; Hermann D; Becker R; Eylers H; Hein R; Baars W; Brinkmann A; Schwinzer R; Niemann H; Petersen B
    Xenotransplantation; 2019 Nov; 26(6):e12525. PubMed ID: 31119817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Artificial antigen-presenting cells expressing CD80, CD70, and 4-1BB ligand efficiently expand functional T cells specific to tumor-associated antigens.
    Zeng W; Su M; Anderson KS; Sasada T
    Immunobiology; 2014 Aug; 219(8):583-92. PubMed ID: 24713579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Presentation of native TROP-2 tumor antigens to human cytotoxic T lymphocytes by engineered antigen-presenting cells.
    Mangino G; Grazia Capri M; Barnaba V; Alberti S
    Int J Cancer; 2002 Oct; 101(4):353-9. PubMed ID: 12209960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Large-scale expansion of Vγ9Vδ2 T cells with engineered K562 feeder cells in G-Rex vessels and their use as chimeric antigen receptor-modified effector cells.
    Xiao L; Chen C; Li Z; Zhu S; Tay JC; Zhang X; Zha S; Zeng J; Tan WK; Liu X; Chng WJ; Wang S
    Cytotherapy; 2018 Mar; 20(3):420-435. PubMed ID: 29402645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell.
    Butler MO; Lee JS; Ansén S; Neuberg D; Hodi FS; Murray AP; Drury L; Berezovskaya A; Mulligan RC; Nadler LM; Hirano N
    Clin Cancer Res; 2007 Mar; 13(6):1857-67. PubMed ID: 17363542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of an artificial antigen-presenting cell to propagate cytolytic CD19-specific T cells.
    Numbenjapon T; Serrano LM; Singh H; Kowolik CM; Olivares S; Gonzalez N; Chang WC; Forman SJ; Jensen MC; Cooper LJ
    Leukemia; 2006 Oct; 20(10):1889-92. PubMed ID: 17041638
    [No Abstract]   [Full Text] [Related]  

  • 19. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB.
    Maus MV; Thomas AK; Leonard DG; Allman D; Addya K; Schlienger K; Riley JL; June CH
    Nat Biotechnol; 2002 Feb; 20(2):143-8. PubMed ID: 11821859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy.
    Zhang H; Snyder KM; Suhoski MM; Maus MV; Kapoor V; June CH; Mackall CL
    J Immunol; 2007 Oct; 179(7):4910-8. PubMed ID: 17878391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.